At Manatee Memorial Hospital (MMH), proven expertise in minimally invasive mitral valve repair is not just about advanced ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter mitral valve repair improved clinical outcomes in patients with HF across all quartiles of mitral ...

The US Food and Drug Administration (FDA) has expanded the indication for the MitraClip (Abbott) device to include patients with normal mitral valves who develop symptoms of heart failure and moderate ...

Why are we asking for donations? Why are we asking for donations? This site is free thanks to our community of supporters. Voluntary donations from readers like you keep our news accessible for ...

BOSTON, MA—(UPDATED) Patients with severe symptomatic degenerative mitral regurgitation (MR) ineligible for surgery fare just as well when treated with the Pascal device (Edwards Lifesciences) as ...

Among a series of 2,500 patients with mitral regurgitation (MR) treated with the MitraClip (Abbott) in the United States, nearly two-thirds had preexisting CAD, and this was associated with an ...

Please provide your email address to receive an email when new articles are posted on . BOSTON — A novel mitral valve transcatheter edge-to-edge repair system was noninferior to an existing system in ...

PHILADELPHIA-- A retrospective study led by researchers from Penn Medicine found that with MitraClip for treatment of secondary mitral regurgitation (MR), a heart disease associated with problems in ...

Cardiovascular diseases or heart problems are still one of the leading causes of death across the globe, and these include such conditions as coronary artery diseases, hypertension, stroke, and many ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window BOSTON -- ...

In 2013, the FDA approved an implantable device to treat leaky heart valves. Among its inventors was Mehmet Oz, the former television personality and former U.S. Senate candidate widely known as "Dr.

Abbott Laboratories, Inc. ABT recently presented late-breaking data from the Landmark COAPT trial for MitraClip, demonstrating the long-term benefits of the device in patients fighting heart failure.